About Heterogeneous nuclear ribonucleoproteins A2/B1
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) is a protein
from Homo sapiens identified by UniProt accession
P22626, 353 residues long.
MolForge cross-references it against 0 known binders and
375 disease associations.
Target properties
| Protein name | Heterogeneous nuclear ribonucleoproteins A2/B1 |
| UniProt accession | P22626 |
| Gene | HNRNPA2B1 |
| Organism | Homo sapiens |
| Length | 353 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (375)
Diseases linked to this target (Open Targets).
- inclusion body myopathy with Paget disease of bone and frontotemporal dementia · score 0.58
- neurodegenerative disease · score 0.47
- adult T-cell leukemia/lymphoma · score 0.37
- prostate adenocarcinoma · score 0.37
- oculopharyngodistal myopathy · score 0.37
- Muscular dystrophy · score 0.37
- carcinoma of liver and intrahepatic biliary tract · score 0.37
- congenital myopathy · score 0.37
- muscular dystrophy · score 0.37
- hepatocellular carcinoma · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P22626-F1 | alphafold | PREDICTED | 69.16 | — |
Amino-acid sequence (353 residues)
MEKTLETVPL ERKKREKEQF RKLFIGGLSF ETTEESLRNY YEQWGKLTDC VVMRDPASKR SRGFGFVTFS SMAEVDAAMA ARPHSIDGRV VEPKRAVARE ESGKPGAHVT VKKLFVGGIK EDTEEHHLRD YFEEYGKIDT IEIITDRQSG KKRGFGFVTF DDHDPVDKIV LQKYHTINGH NAEVRKALSR QEMQEVQSSR SGRGGNFGFG DSRGGGGNFG PGPGSNFRGG SDGYGSGRGF GDGYNGYGGG PGGGNFGGSP GYGGGRGGYG GGGPGYGNQG GGYGGGYDNY GGGNYGSGNY NDFGNYNQQP SNYGPMKSGN FGGSRNMGGP YGGGNYGPGG SGGSGGYGGR SRY
Explore Heterogeneous nuclear ribonucleoproteins A2/B1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets